IL6 and COVID-19: Janus kinase (JAK) inhibitors (baricitinib, tofacitinib, imatinib) showed promising results for reducing mortality and intubation rates and have been approved in many countries for the treatment of the same population of COVID-19 patients as for IL-6 and IL-1 antagonists [48].